SAN DIEGO, June 5, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) is active in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM), including non-epithelioid MPM, which carries an unfavorable prognosis and historically responds poorly to…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2017-06-05 15:07:422018-01-17 15:18:10Polaris Lead Therapeutic ADI‑PEG 20 in Combination with First Line Chemotherapy Is Active in Argininosuccinate Synthetase Deficient Mesothelioma
SAN DIEGO, April 20, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) demonstrated a good safety profile and a strong efficacy signal in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM) and non-small cell lung carcinoma…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2017-04-20 15:21:072018-01-17 15:21:22Polaris Provides Early Evidence of Response to Arginine Depletion by ADI‑PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors
SAN DIEGO, January 20, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI‑PEG 20 in combination with low-dose cytarabine for the treatment of acute myeloid leukemia (AML) in older patients. In addition to a global phase 2/3 study in…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2017-01-20 15:23:492018-01-17 15:25:06Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 Plus Cytarabine in Older Patients with Acute Myeloid Leukemia
SAN DIEGO, January 19, 2017 – Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI‑PEG 20 with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in patients with advanced hepatocellular carcinoma (HCC) and other gastrointestinal malignancies. The results will be presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco.
SAN DIEGO, Nov. 8, 2016 /PRNewswire/ — Polaris Group announced today that ADI‑PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of radiation in argininosuccinate synthetase (ASS1) deficient pancreatic tumors according to results presented by researchers from MD Anderson Cancer Center at the annual meeting of the American Society for Radiation Oncology (ASTRO).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-11-08 09:12:042018-02-19 09:15:21ADI‑PEG 20 Radio-sensitizes Pancreatic Cancer Cells by Amplifying Early Endoplasmic Reticulum Stress
SAN DIEGO, Oct. 24, 2016 /PRNewswire/ — Polaris Group announced today that ADI‑PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology and Immunotherapy conference in Boston.
CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI‑PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI‑PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-06-06 09:21:322018-02-19 09:23:35Polaris Group Reports Phase III Study Results of ADI‑PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma
CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in argininosuccinate synthetase (ASS1) deficient thoracic tumors.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-06-06 09:16:242018-02-19 09:20:32FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI‑PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors
CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI‑PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI‑PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-06-03 18:00:222018-02-19 18:01:39ADI‑PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer
SAN DIEGO, May 16, 2016 — Polaris Group announced today that it has received notification that the United States Patent and Trademark Office will issue to Polaris Group a new utility patent that will contain claims protecting the pharmaceutical composition of ADI‑PEG 20 which Polaris Group plans to commercialize upon receiving regulatory approval, as well as claims covering therapeutic use of the compositions of ADI‑PEG 20 for the treatment of a variety of cancer indications.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-05-16 18:02:362018-02-19 18:04:30Polaris Group Announces Issuance of New Patent Protecting Lead Product Candidate ADI‑PEG 20
Polaris Lead Therapeutic ADI‑PEG 20 in Combination with First Line Chemotherapy Is Active in Argininosuccinate Synthetase Deficient Mesothelioma
NewsSAN DIEGO, June 5, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) is active in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM), including non-epithelioid MPM, which carries an unfavorable prognosis and historically responds poorly to…
Polaris Provides Early Evidence of Response to Arginine Depletion by ADI‑PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors
NewsSAN DIEGO, April 20, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) demonstrated a good safety profile and a strong efficacy signal in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM) and non-small cell lung carcinoma…
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 Plus Cytarabine in Older Patients with Acute Myeloid Leukemia
NewsSAN DIEGO, January 20, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI‑PEG 20 in combination with low-dose cytarabine for the treatment of acute myeloid leukemia (AML) in older patients. In addition to a global phase 2/3 study in…
ADI‑PEG 20 plus FOLFOX Shows Robust Anti-tumor Activity in Advanced Hepatocellular Carcinoma
NewsSAN DIEGO, January 19, 2017 – Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI‑PEG 20 with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in patients with advanced hepatocellular carcinoma (HCC) and other gastrointestinal malignancies. The results will be presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco.
ADI‑PEG 20 Radio-sensitizes Pancreatic Cancer Cells by Amplifying Early Endoplasmic Reticulum Stress
NewsSAN DIEGO, Nov. 8, 2016 /PRNewswire/ — Polaris Group announced today that ADI‑PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of radiation in argininosuccinate synthetase (ASS1) deficient pancreatic tumors according to results presented by researchers from MD Anderson Cancer Center at the annual meeting of the American Society for Radiation Oncology (ASTRO).
ADI‑PEG 20 Can Boost Anti-Tumor Immune Surveillance
NewsSAN DIEGO, Oct. 24, 2016 /PRNewswire/ — Polaris Group announced today that ADI‑PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology and Immunotherapy conference in Boston.
Polaris Group Reports Phase III Study Results of ADI‑PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma
NewsCHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI‑PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI‑PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).
FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI‑PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors
NewsCHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in argininosuccinate synthetase (ASS1) deficient thoracic tumors.
ADI‑PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer
NewsCHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI‑PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI‑PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).
Polaris Group Announces Issuance of New Patent Protecting Lead Product Candidate ADI‑PEG 20
NewsSAN DIEGO, May 16, 2016 — Polaris Group announced today that it has received notification that the United States Patent and Trademark Office will issue to Polaris Group a new utility patent that will contain claims protecting the pharmaceutical composition of ADI‑PEG 20 which Polaris Group plans to commercialize upon receiving regulatory approval, as well as claims covering therapeutic use of the compositions of ADI‑PEG 20 for the treatment of a variety of cancer indications.